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Abstract
Background: Non-cystic fibrosis bronchiectasis is characterized by the irreversible dilatation of the medium-sized
bronchi as a result of airway injury from recurrent or chronic inflammation and lower respiratory tract infections.
Bronchiectasis airways are commonly colonized with bacterial species. Infections of the airways play important role
in bronchiectasis exacerbations. The non-specific prevention of recurrent airway infections by immunostimulating
agents has gained growing interest. OM-85, consisting of extracts of eight kinds of bacteria important in respiratory
infections, could support the respiratory tract resistance to the pathogens. OM-85 has been shown to be a
benefit by decreasing the risk of acute exacerbation of chronic obstructive pulmonary disease (COPD) in several
perspective clinical trials. Exacerbation of bronchiectasis substantially contributes to a more rapid decline in lung
function, reduced quality of life, and healthcare costs. In this context, we plan to conduct a clinical trial to
investigate the PReventive effect of OM-85 on Bronchiectasis Exacerbation in Chinese patients (iPROBE).
Methods/Design: This study is designed as a prospective, randomized, double blind, placebo-controlled multicenter
trial. A total of 244 patients with bronchiectasis, who have had at least one exacerbation of bronchiectasis in the
previous year, will be included. The subjects will randomly receive two courses of 7 mg of OM-85 or a matching
placebo. The treatment dose of OM-85 will be one daily capsule taken orally for 10 days each month for 3 consecutive
months at the beginning of the study, followed by 3 months of no drug. This schedule will repeat until the patient has
been seen for one year.
Discussion: We will investigate whether long-term treatment with an oral immunostimulant (OM-85) could decrease
exacerbations of bronchiectasis over a one-year period. We will also assess other relevant outcomes, including the
rate of event-based exacerbation, lung function parameters, and total scores judged by the St George’s respiratory
questionnaire, Leicester cough questionnaire, and inflammatory index. We hope that this study will provide new
information on the preventive effects of OM-85 on bronchiectasis exacerbations and will address a knowledge gap for
this understudied disease.
Trial registration: This study is registered at www.clinicaltrials.gov (identifier NCT01968421) on 19 October 2013.
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Bronchiectasis is a common, however, under-recognized
chronic respiratory disease [1-3]. The prevalence of bron-
chiectasis in adult populations worldwide is unknown
[3,4]. In the United States, an estimated prevalence of
bronchiectasis in adults was 52 in every 100,000 people,
and increased by 8.7% per year between 2000 and 2007
[5]. Non-cystic fibrosis bronchiectasis is pathologically
characterized by an irreversible dilatation of the medium-
sized bronchi as a result of airway injury due to recurrent
or chronic inflammation and infection. Clinical features of
bronchiectasis include chronic production of sputum
(often mucopurulent or purulent in nature), persistent
bacterial colonization, recurrent lower respiratory tract
infections, and hemoptysis, with breathlessness charac-
terized by mild to moderate airflow obstruction, lethargy,
and reduced health status [2].
Bronchiectatic airways are often colonized with bacte-
rial species such as Haemophilus influenzae, Strepto-
coccus pneumoniae and Pseudomonas aeruginosa [2,6].
Thus, it is believed that infections of the airways fre-
quently play an important role in bronchiectasis exacer-
bations [7]. Macrolide antibiotics with anti-inflammatory
and immunomodulatory properties are increasingly pre-
scribed for subjects with this disease [8]. Recently, Wong
et al. demonstrated that azithromycin three times a
week for six months significantly decreases the incidence
of bronchiectasis exacerbations [9]. However, widespread
use of long-acting macrolides, particularly azithromycin,
risks significantly increasing population antimicrobial re-
sistance as well as potential adverse drug effects [10].
Abnormalities in innate and adaptive immunity may
cause a predisposition to bronchiectasis. Progressive
lung damage in bronchiectasis results from a ‘vicious
cycle’ of recurrent bacterial infection and a deregulated
inflammatory response. This indicates the failure of the
host defenses that have evolved to maintain the sterility
of the respiratory tract [7,11]. The non-specific preven-
tion of recurrent airway infections by immunostimula-
ting agents has gained growing scientific interest over
the past 40 years and is increasingly applied in different
clinical situations [12].
OM-85 has been known to support the respiratory tract
resistance to pathogens. It consists of extracts of eight
kinds of bacteria thought to be important in respiratory
infections. OM-85 does not appear to be a bacterial vac-
cine but is thought to function by activating pulmonary
macrophages, increasing the ratio of CD4 to CD8 lympho-
cytes, and changing the level of a variety of cytokines in
the lung. The changes are thought to be indicative of an
increased level of host defense against a wide variety of
pathogens including both viruses and bacteria [12]. Thus,
the protective effect of OM-85 implicates infection as an
important player in the pathogenesis of exacerbations but
does not indicate a specific class of infectious agent. As
such, the potential benefit of OM-85 has been evaluated
in a variety of chronic respiratory diseases. The best stu-
died condition is chronic obstructive pulmonary disease
(COPD), in which there have been several randomized
controlled trials showing evidence of benefit by signifi-
cantly reducing the incidence of exacerbations of COPD
of all severities [13,14]. Bronchiectasis exacerbations con-
tribute substantially to rapid decline in lung function, re-
duced quality of life, and the medical costs. In patients
with bronchiectasis, exacerbations occur with a frequency
rate of 2.6 exacerbations annually [15].
The purpose of this multicenter, randomized, con-
trolled trial is to investigate the PReventive effect
of OM-85 on Bronchiectasis Exacerbations in adult
Chinese patients (iPROBE). The iPROBE project is gene-
rally based on the concept that the majority of patients
with bronchiectasis often suffer from exacerbations.
Aims of the study
This study is structured as a multicenter, randomized,
double blind, placebo-controlled trial (RCT) to study the
effect of treatment with OM-85 in preventing acute
exacerbation in patients with bronchiectasis (Figure 1).
The primary goals of this study include two domains:
(1) a reduction in the numbers of acute exacerbation;
and (2) percentage of patients free of event-based ex-
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Figure 1 Flow chart of the patients through the clinical trial.
BV: broncho-vaxom (OM-85).
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tory Questionnaire (SGRQ); Leicester Cough Questionnaire
(LCQ); use of antibiotics and rapid-acting bronchodilator;
lung function parameters: forced expiratory volume in first
second (FEV1) predicted, forced vital capacity (FVC),
FEV1/FVC, immunoglobulin (Ig), total immunoglobulin E
(TIgE), rheumatic factor (RF); C-reactive protein (CRP) in
serum; and sputum bacteria clearance.
Methods/Design
Overall design and patient selection
This RCT study will be performed at 10 major medical
centers in Beijing, Shenyang, Tianjin, Zhejiang, and
Shanghai, China. We plan to recruit 244 patients with
bronchiectasis diagnosed using high-resolution com-
puted tomography (HRCT). The patients should have
had at least one exacerbation requiring antibiotics in the
previous year prior to recruitment. Participants will be
invited to visit the clinical centers on six occasions and
follow up will be conducted by telephone on two occa-
sions during the year (Figure 2). The investigations to be
performed are shown in Table 1.
An exacerbation will be defined as the patient reporting
four or more of the following symptoms: change in spu-
tum production, increased dyspnea, increased cough, fever
over 38°C, increased wheezing, decreased exercise tole-
rance, fatigue, malaise, lethargy, reduced pulmonary func-
tion, changes in chest sounds or radiographic changes
consistent with a new infectious process [3].
The study will occur over a three-year period. Recruit-
ment of cases and controls to the study will be per-
formed over a two-year period (May 2013 to May 2015).
The treatment period will last for one year. The end of
the study is defined by the last visit of the last partici-
pant (Figure 2).
Randomization
All eligible subjects will be randomized using block
randomization sequences generated by computer. The
subjects will be assigned at a 1:1 ratio with a permuted
block size and sequential assignment, stratified by the
center. Treatment allocation numbers will be entered
into individually sealed envelopes containing a number
that is concealed to the treatment allocation. The alloca-
tion list will be stored in a safe place in each study site
and accessed by a non-investigator independently. In
the event of a medical emergency the individual’s
randomization code and group allocation could be
identified.
Intervention
The subjects will randomly receive two courses of 7 mg
of OM-85 or matching placebo. The treatment dose of
OM-85 of will be one daily capsule taken orally for 10
days each month for 3 consecutive months at the begin-
ning of the study, followed by 3 months of no drug. This
schedule will repeat, and then be followed until the pa-
tient has been seen for one year. During the whole study
period, subjects will be followed at the outpatient clinics
1, 2, 4, 7, 10, and 12 months after initiating the study
(Figure 2). During the visits, Table 1 shows the tests that
will be performed.
Eligibility criteria
Participants were eligible for inclusion in the study when
they are 18 years or older diagnosed with bronchiectasis
by HRCT of the chest within three years of study inclu-
sion, and having had at least one acute exacerbation in
the previous year when recruiting.
Exclusion criteria include history of cystic fibrosis;
hypogammaglobulinemia; allergic bronchopulmonary as-
pergillosis; active tuberculosis; subject has been assigned
to treatment in a study of the medication under investi-
gation in this study in the previous six months; subject
has a history of chronic alcohol or drug abuse within the
last six months judged by the investigators; hypersen-
sitivity to any components of OM85; subject has
received an immunostimulant in last three months;
Visit 2 Visit 3 
Visit 8 follow up)
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Figure 2 Treatment periods and visits.
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or kidney impairment, and immuno-related diseases.
Subjects are free to withdraw from the study at any
time, without prejudice to their continuing care.
Investigators should attempt to obtain information on
subjects in the case of withdrawal or discontinuation.
For subjects considered as lost to followup the investiga-
tor should make an effort (at least one phone call and
one written message to the subject), and document their
effort (date and summary of the phone call and a copy
of the written message in the source documents) to
complete the final evaluation. All results of these eva-
luations and observations, together with a narrative de-
scription of the reason(s) for removing the subject, must
be recorded in the source documents. The case report
form must document the primary reason for withdrawal
or discontinuation. Investigators should contact the
Medical Monitor whenever possible to discuss the with-
drawal of a subject in advance.
Written informed consent approved by an Institutional
Review Board (IRB) or Independent Ethics Committee
(IEC) is signed and dated by the subject.
Sample size
To detect a true difference in the primary outcome mea-
sures of the number of bronchiectasis exacerbations and
the time to first exacerbation, a total of 244 subjects
(122 per arm) will be required. This calculation is based
on the 80% probability to detect a 33% reduction in the
numbers of bronchiectasis exacerbation and a signifi-
cantly greater median time to the first exacerbation by
OM-85 treatment. The incidences of bronchiectasis
exacerbation were reported to be between 1.5 and 6.5
times per patient per year [3,16], and median time to
first time to exacerbation to be 85 days in a clinical trial
lasting over a one-year period [9].
Statistics
There are three analysis populations in the study: full
analysis set (FAS), per protocol set (PPS) and safety set.
The primary endpoint will be analyzed on FAS, which is
the primary population, and will be supported by PPS.
The secondary endpoint and baseline information will
be analyzed on FAS. Safety analyses will be performed
on the safety set.
The primary efficacy variable is the numbers of acute
exacerbation during the treatment. It will be analyzed on
FAS population and supported by PPS population. Sta-
tistical description and statistical inference will be con-
ducted. Mean, standard deviation, median, maximum
and minimum will be presented as a statistical descrip-
tion for each study group.
Statistical inference consists of a parameter estimation
and hypothesis test. For categorical variables, frequency
and proportion will be summarized by group. Com-
parison between two groups will be performed using
Student-t test or Wilcoxon test depending on data distri-
bution. A two-tailed 95% confidence interval of the dif-
ference between groups will also be presented.
The categorical data will be analyzed by the Pearson
chi-square test or Fisher exact test. The change before
and after treatment within each group will be described
and tested by the paired-t test or signed-ranks test.
The interval to the first time of acute exacerbation will
be analyzed as survival data. Kaplan-Meier curves of two
groups will be presented and thelog-rank test will be
used to test the difference between two groups.
All analyses will follow the intention-to-treat principle.
We will also employ the following methods to minimize
the potential effects of missing data or dropout. First,
when the study treatment is discontinued, we will try to
obtain consent from the participants to collect data on
treatments and outcomes. W we will use an estimating-
equation method to impute missing data [17] in our pri-
mary analysis; and we will conduct a sensitivity analysis
by using simple imputation methods.
Safety analysis
Analysis on safety will be done using the safety set. All
adverse events will be coded using the last version of
Medical Dictionary for Regulatory Activities. Total fre-
quency and incidence of adverse event (AE) and severe
AE (SAE) will be described. The frequency of AE in each
group will be tabulated by system organ class and the
Table 1 Overview of clinic visits and measurements
Day 1 Month 1 Month 3 Month 5 Month 7 Month 9 Month 12
Informed consent ×
Demographic data ×
Blood works × × × ×
Leicester cough score × × ×××××
SGRQ score × × ×××××
Lung function test × × ×
Sputum microbiology × × ×
SGRQ: St George’s respiratory questionnaire.
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study will be summarized by each group. AE-related
(definitely related, probably related, and possibly related)
will be described and listed separately by the two groups.
AE leading to withdrawal from the study will be des-
cribed and summarized separately by the two groups.
Ethical approval
The study has been approved by the Central Ethics
Committee of Peking Union Medical College Hospital.
The detailed study will be explained to the patient prior
to enrolment in the study by the investigator. The
explanation will include the type, the purpose, the tests
to be performed, and any potential hazards. A written
informed consent will be obtained from each participant.
The patient can withdraw from the study at any time,
without any repercussion for the ongoing care.
The study will be conducted according to the Inter-
national Conference for Harmonization (ICH) principles
of Good Clinical Practice (GCP) and the Declaration of
Tokyo (2004). The investigator will conduct all aspects
of this study in accordance with all national and regional
laws of the pertinent regulatory authorities.
Discussion
With the widespread availability of chest HRCT, bron-
chiectasis is becoming increasingly recognized. It has
been concluded that bronchiectasis remains a common
and important cause of respiratory disease [4]. There is
an overlap between COPD and bronchiectasis, with a re-
ported incidence of bronchiectasis in COPD being bet-
ween 29% and 50% [18]. There are also reports of a high
prevalence in relatively isolated populations with poor
access to health care and high rates of respiratory tract
infection during childhood [19]. However, treatment
of bronchiectasis is unsatisfactory with only very small
trials being conducted, and there are currently no dis-
ease-modifying drugs. Immunomodulation agents such
as low-dose macrolides have also been shown to have
some efficacy, although more data are needed to advo-
cate their long-term usage. Some studies have shown
that chronic azithromycin treatment increases the de-
velopment of macrolide-resistant organisms such as
S. pneumoniae [10]. However, azithromycin could also
predispose patients with cystic fibrosis to the develop-
ment of non-tuberculous mycobacterial infection [9]. In
addition, there is new evidence that the combination of
azithromycin and tobramycin, through the alteration of
intracellular antibacterial activity, may lead to even
worse bacteriological outcomes. However, recent evi-
dence has shown that azithromycin may antagonize in-
haled tobramycin when targeting P. aeruginosa in cystic
fibrosis [20]. Finally, an optimum duration of treatment
with azithromycin is unclear.
A possible mechanism for bronchiectasis is a signifi-
cant infection in early childhood which causes structural
damage to the developing lung, allowing perpetual bac-
terial infection. Over time, persistent infection may then
result in chronic inflammation, resulting in tissue dam-
age and impaired mucociliary motility. This in turn leads
to more infection, with a cycle of progressive inflamma-
tion, causing lung damage. Based on the ‘vicious cycle’
model of the pathophysiology of bronchiectasis, persist-
ent infection and a defect in host defense are two factors
for the development of this condition [7,11].
Some observations have shown that airway inflamma-
tion in bronchiectasis is due to a deregulated cytokine
network independent of bacterial airway colonization
[7]. The iPROBE study is taking an approach that is dis-
tinct from other studies using antibiotics (oral, nebu-
lized) to reduce the bacterial load and then decrease
lower airway inflammation [9,19,21]. OM-85 would be
used to improve host defense and reduce airway inflam-
mation, allowing airway healing and thus modifying the
long-term course of disease. The rationale of the current
study for choosing OM-85 includes its immunomodula-
tory property and potential activity based on common
respiratory tract bacterial isolates. OM-85 is not a new
drug, having apparently been available in Europe over 40
years with a very good safety profile. OM-85 is relatively
easy to administer, so it is likely that patient compliance
would be as good as it is with mucolytic therapy.
The variables (primary and secondary) chosen in this
study reflect the nature of bronchiectasis, and have been
widely adopted by the majority of clinical trials on bron-
chiectasis [22,23].
In summary, this doubleblind RCT examining the pre-
vention of OM-85 against exacerbation of bronchiectasis
addresses a gap in the knowledge and treatment for this
neglected disease. If the intervention is efficacious, it
would provide long-term benefits for patients with bron-
chiectasis and improve the prognosis of this condition.
Trial status
The trial is scheduled to begin recruiting participants
from May 2013, and expected to complete the enroll-
ment by May 2015.
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